This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2012 Jan 17;9(2):62.

doi: 10.1038/nrgastro.2011.265.

IBD: Phase II results for IBD drugs

PMID: 22249735
DOI: 10.1038/nrgastro.2011.265

Comment

IBD: Phase II results for IBD drugs

Isobel Franks. Nat Rev Gastroenterol Hepatol. 2012.

. 2012 Jan 17;9(2):62.

doi: 10.1038/nrgastro.2011.265.

Author

PMID: 22249735
DOI: 10.1038/nrgastro.2011.265

No abstract available

PubMed Disclaimer

Comment on

Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease.
Prantera C, Lochs H, Grimaldi M, Danese S, Scribano ML, Gionchetti P; Retic Study Group (Rifaximin-Eir Treatment in Crohn's Disease). Prantera C, et al. Gastroenterology. 2012 Mar;142(3):473-481.e4. doi: 10.1053/j.gastro.2011.11.032. Epub 2011 Dec 6. Gastroenterology. 2012. PMID: 22155172 Clinical Trial.

References

1. Inflamm Bowel Dis. 2012 Aug;18(8):1470-9 - PubMed
1. Gastroenterology. 2012 Mar;142(3):473-481.e4 - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.